← Back

Wire · opportunities

Dronabinol for PTSD Nightmares Is Promising, and the Dual Diagnosis Question Changes ...

Published

24 August 2026

Topic

opportunities

Sectors

Mental Health

Geography

United States

Source

Read at clinicaltrialvanguard.com

Verified

Fusion42 · 24 August 2026 · Fusion42 review

A recent randomized trial showed dronabinol, a synthetic THC, significantly reduced PTSD nightmares, suggesting a new treatment avenue beyond prazosin. However, the study did not address patients with comorbid substance use disorders (SUD), a large portion of the PTSD population, creating clinical and regulatory challenges for broad adoption.

This Wire brief sits within Fusion42's coverage of Mental Health.

◆ The Wire takeaway

Prescribing dronabinol for PTSD nightmares confronts you with a major clinical blind spot: comorbid substance use disorder patients are excluded from trials but form half your patient base. Address this gap immediately or risk losing market access as guidelines and real-world needs diverge.

Coverage

1 source · 24 Aug 2026

Related on Wire

Topics

Mental Healthptsddronabinolsynthetic-thcsubstance-use-disordermental-health-treatmentoff-label-use